HBK Investments’s Genomic Health, Inc. GHDX Stock Holding History

HBK Investments’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-34,939	Closed	-$2.45M	–	1208
2019 Q1	$2.45M	Sell	34,939 -60,108	-63%	-$4.46M	0.02%	461
2018 Q4	$6.12M	Buy	95,047 +49,651	+109%	+$3.48M	0.06%	235
2018 Q3	$3.19M	Buy	45,396 +20,796	+85%	+$1.22M	0.03%	396
2018 Q2	$1.24M	Buy	24,600 +15,000	+156%	+$595K	0.01%	592
2018 Q1	$300K	Buy	+9,600	New	+$319K	﹤0.01%	855
2017 Q4	–	Sell	-11,585	Closed	-$372K	–	1209
2017 Q3	$372K	Sell	11,585 -515	-4%	-$16.2K	﹤0.01%	851
2017 Q2	$394K	Sell	12,100 -1,999	-14%	-$63.3K	﹤0.01%	766
2017 Q1	$444K	Sell	14,099 -4,240	-23%	-$125K	﹤0.01%	532
2016 Q4	$539K	Sell	18,339 -12,561	-41%	-$383K	0.01%	547
2016 Q3	$894K	Buy	30,900 +234	+0.8%	+$6.52K	0.01%	533
2016 Q2	$794K	Sell	30,666 -5,105	-14%	-$136K	0.01%	621
2016 Q1	$886K	Buy	+35,771	New	+$982K	0.01%	621
2015 Q3	–	Sell	-9,181	Closed	-$255K	–	1182
2015 Q2	$255K	Buy	+9,181	New	+$259K	﹤0.01%	852

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HBK Investments's GHDX Position: Q2 2019 in Review

HBK Investments sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 34,939 shares — an estimated $2.45M sold.

HBK Investments first reported a position in GHDX in Q2 2015 and held it in 13 quarters. The position peaked at $6.12M in Q4 2018. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

HBK Investments reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
HBK Investments sold 34,939 Genomic Health, Inc. shares in Q2 2019, an estimated $2.45M.
HBK Investments first reported a position in Genomic Health, Inc. in Q2 2015 and held it in 13 quarters.
HBK Investments's Genomic Health, Inc. position peaked at $6.12M in Q4 2018.
215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.